Bamco Inc. NY Raises Stock Holdings in Astrazeneca Plc $AZN

Bamco Inc. NY grew its position in Astrazeneca Plc (NYSE:AZN) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 140,008 shares of the company’s stock after acquiring an additional 12,000 shares during the quarter. Bamco Inc. NY’s holdings in Astrazeneca were worth $10,741,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Binnacle Investments Inc increased its holdings in shares of Astrazeneca by 21.8% in the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock valued at $51,000 after acquiring an additional 118 shares during the period. Chapin Davis Inc. boosted its stake in Astrazeneca by 3.3% during the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after purchasing an additional 120 shares during the period. 44 Wealth Management LLC grew its position in Astrazeneca by 0.7% during the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock worth $1,283,000 after purchasing an additional 124 shares during the last quarter. CoreCap Advisors LLC increased its stake in Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after purchasing an additional 125 shares during the period. Finally, Highline Wealth Partners LLC increased its stake in Astrazeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares during the period. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. HSBC reiterated a “buy” rating and set a $108.00 target price on shares of Astrazeneca in a research note on Wednesday, December 10th. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, December 9th. Wall Street Zen downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Friday, February 6th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $95.75.

Astrazeneca Stock Performance

Shares of AZN stock opened at $190.20 on Monday. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The firm has a market capitalization of $294.98 billion, a PE ratio of 32.77, a PEG ratio of 1.43 and a beta of 0.32. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Monday, March 23rd. Investors of record on Friday, February 20th will be paid a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date of this dividend is Friday, February 20th. Astrazeneca’s dividend payout ratio is presently 66.26%.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.